KTC1101

KTC1101 is an orally active pan-PI3K inhibitor. KTC1101 can inhibit the PI3K signaling pathway, reduce downstream AKT and mTOR phosphorylation, and reduces the expression of Ki67. The anti-tumor effect of KTC1101 has a dual mechanism of action: directly inhibiting tumor cell growth and dynamically enhancing immune response[1].

Product Specifications

CAS Number

[2764833-47-6]

UNSPSC

12352005

Target

Akt; mTOR; PI3K

Type

Reference compound

Related Pathways

PI3K/Akt/mTOR

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/ktc1101.html

Purity

98.09

Solubility

DMSO : 33.33 mg/mL (ultrasonic)

Smiles

FC(F)C1=NC2=C(OC)C=C(N)C=C2N1C3=NC(N4CCOCCC4)=NC(N5CCOCC5)=N3

Molecular Formula

C21H26F2N8O3

Molecular Weight

476.48

References & Citations

[1]Peng X, et al. A novel pan-PI3K inhibitor KTC1101 synergizes with anti-PD-1 therapy by targeting tumor suppression and immune activation. Mol Cancer. 2024 Mar 14;23 (1) :54.